v3.26.3
Equity-Based Compensation - Additional Information (Details) - USD ($)
$ / shares in Units, $ in Thousands
3 Months Ended 9 Months Ended
Sep. 30, 2026
Sep. 30, 2025
Sep. 30, 2026
Sep. 30, 2025
Mar. 31, 2026
Mar. 31, 2025
Aug. 20, 2020
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]              
Recognized stock-based compensation expense $ 18,837 $ 15,802 $ 53,782 $ 45,451      
Equity-based compensation expense 18,837 15,802 53,782 45,451      
Employee Stock Option              
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]              
Intrinsic value of stock options exercised $ 33,100 $ 8,600 $ 103,500 $ 16,000      
Weighted-average fair value of options granted $ 78.35 $ 33.67 $ 64.99 $ 22.73      
Recognized stock-based compensation expense $ 13,316 $ 12,545 $ 38,852 $ 36,506      
Unrecognized stock-based compensation expense 108,000   $ 108,000        
Unrecognized compensation cost, recognition period     3 years 3 months 18 days        
Equity-based compensation expense 13,316 12,545 $ 38,852 36,506      
Employee Stock Option | Research and Development Arrangement [Member]              
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]              
Recognized stock-based compensation expense 6,843 5,919 19,072 17,615      
Equity-based compensation expense 6,843 5,919 19,072 17,615      
Employee Stock Option | General and Administrative [Member]              
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]              
Recognized stock-based compensation expense 6,473 6,626 19,780 18,891      
Equity-based compensation expense 6,473 6,626 19,780 18,891      
Restricted Stock              
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]              
Recognized stock-based compensation expense 5,300 $ 2,800 14,200 $ 8,000      
Unrecognized stock-based compensation expense $ 72,300   $ 72,300        
Unrecognized compensation cost, recognition period     3 years 1 month 6 days        
Granted 265,100 243,950 688,067 736,050      
Equity-based compensation expense $ 5,300 $ 2,800 $ 14,200 $ 8,000      
Restricted Stock | Research and Development Arrangement [Member]              
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]              
Recognized stock-based compensation expense 3,900 2,300 10,400 5,800      
Equity-based compensation expense 3,900 2,300 10,400 5,800      
Restricted Stock | General and Administrative [Member]              
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]              
Recognized stock-based compensation expense 1,400 500 3,800 2,200      
Equity-based compensation expense $ 1,400 500 $ 3,800 2,200      
2020 Plan              
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]              
Number of shares authorized for issuance under plan             4,457,370
Maximum number of shares to be issued, percentage     4.00%        
Shares remaining available for future grants 6,342,748   6,342,748        
Weighted-average fair value of options granted     $ 97.53        
Recognized stock-based compensation expense $ 200 $ 0 $ 500 $ 0      
Performance stock options vesting 60.00%   60.00%     40.00%  
Second clinical milestone vesting percentage           40.00%  
Third clinical milestone vesting percentage 15.00%   15.00%     20.00%  
Granted 0 0 95,000 88,000      
Option Indexed to Issuer's Equity, Strike Price     $ 30.17        
Performance stock options outstanding 88,000   88,000        
Equity-based compensation expense $ 200 $ 0 $ 500 $ 0      
2020 Plan | Restricted Stock              
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]              
Granted 0 0 73,672 285,723      
2020 Plan | Performance Stock              
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]              
Weighted-average fair value of options granted     $ 126.09        
Recognized stock-based compensation expense $ 100   $ 400        
Performance stock options vesting         60.00% 40.00%  
Second clinical milestone vesting percentage           40.00%  
Third clinical milestone vesting percentage         15.00% 20.00%  
Granted 0 0 73,672 0      
Option Indexed to Issuer's Equity, Strike Price     $ 30.17        
Equity-based compensation expense $ 100   $ 400        
2020 Plan | Minimum [Member]              
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]              
Performance stock options range 0.00%   0.00%     0.00%  
2020 Plan | Minimum [Member] | Performance Stock              
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]              
Performance stock options range 0.00%   0.00%   0.00%    
2020 Plan | Maximum [Member]              
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]              
Performance stock options range 100.00%   100.00%     100.00%  
2020 Plan | Maximum [Member] | Performance Stock              
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]              
Performance stock options range 100.00%   100.00%   100.00%    
2020 Plan | Executive Officer [Member] | Performance Stock              
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]              
Granted   0   285,723      
2020 ESPP              
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]              
Number of shares authorized for issuance under plan             445,653
Shares remaining available for future grants 2,716,358   2,716,358        
Share-based compensation, description     The 2020 ESPP provides that the number of shares reserved and available for issuance will automatically increase on January 1, 2021 and each January 1 thereafter through January 1, 2030, by the lesser of (i) 438,898 shares of common stock, (ii) 1% of the Company’s outstanding number of shares of common stock on the immediately preceding December 31 or (iii) such lesser number of shares of common stock as determined by the administrator of the 2020 ESPP.        
2020 ESPP | Lesser of Potential Outcome 1              
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]              
Maximum number of shares to be issued, percentage     1.00%        
Number of additional shares authorized     438,898        
2018 Plan | Restricted Stock              
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]              
Granted     761,739